MGH
PET Core
Overview
The Massachusetts General Hospital PET Core is cGMP/FDA registered PET drug manufacturer. It provides investigators with required personnel, equipment and services to design and conduct research studies using positron emission tomography.Services
- Synthesis of radiotracers and radiopharmaceuticals
- PET and SPECT animal and human imaging
- Experimental design
- Validation and regulatory submission of compound for human use
FY 2025 Fee Schedule, effective 10/1/2024
Radiopharmaceuticals Available for Human and Animal Use.
The Core commits its best efforts to successfully complete scheduled studies. However, given the very nature of many PET studies that rely on manufacturing of the radiopharmaceutical and in vivo imaging, the Core cannot cover costs associated with uncompleted studies due to equipment failure or circumstances outside of our control.
A PET/SPECT study that is cancelled or rescheduled within 48 business hours of the original imaging session may incur a fee up to the cost of the cancelled imaging session. A radiotracer production that is not cancelled 48 business hours prior to the production day may incur a fee up to the cost of the produced dose.
* A Mass General Brigham investigator using a Mass General Brigham fund is considered an internal user and will be subject to the institutional overhead rate applied by Mass General Brigham Research Management. The external user fee comprises a direct fee negotiated with the PET Core plus an overhead component. The overhead rate set by Mass General Brigham is 44% for external academic users and 59% for external industry users.
Please send inquiries to:
MGHPETCore@massgeneralbrigham.org
To receive a quote for the MGH Pet Core services, please complete this form: MGH NMMI PET Core Research request
Contact Information
Core Co-Director
Pedram Heidari, MD
heidari.pedram@mgh.harvard.edu
Core Co-Director
Giuliana Arcovio, MBA, RT(N), CNMT
garcovio@mgb.org
Buisness Manager
Slav Lerner
vlerner@mgh.harvard.edu